Active Ingredient History
Nitazoxanide, sold under the brand name Alinia among others, is a broad-spectrum antiparasitic and broad-spectrum antiviral medication that is used in medicine for the treatment of various helminthic, protozoal, and viral infections. It is indicated for the treatment of infection by Cryptosporidium parvum and Giardia lamblia in immunocompetent individuals and has been repurposed for the treatment of influenza. Nitazoxanide has also been shown to have in vitro antiparasitic activity and clinical treatment efficacy for infections caused by other protozoa and helminths; evidence as of 2014 suggested that it possesses efficacy in treating a number of viral infections as well. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Giardiasis (approved 2002)
Adenoviridae Infections (Phase 2/Phase 3)
Amebiasis (Phase 3)
Arthritis, Rheumatoid (Phase 3)
Bronchiolitis (Phase 2)
Caliciviridae Infections (Phase 2/Phase 3)
Clostridioides difficile (Phase 2)
Clostridium Infections (Phase 3)
Cognition Disorders (Phase 2/Phase 3)
Colitis, Ulcerative (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 3)
Coronavirus (Phase 2)
Coronavirus Infections (Phase 4)
COVID-19 (Phase 4)
Crohn Disease (Phase 2)
Cryptosporidiosis (Phase 3)
Diabetes Mellitus, Type 2 (Phase 4)
Diarrhea (Phase 3)
Dyspepsia (Phase 3)
Enterocolitis, Pseudomembranous (Phase 3)
Enterovirus (Phase 3)
Fatty Liver (Phase 2)
Gastritis (Phase 3)
Gastroenteritis (Phase 2)
Growth Disorders (Phase 2/Phase 3)
Helicobacter Infections (Phase 3)
Helicobacter pylori (Phase 3)
Helminthiasis (Phase 1/Phase 2)
Hepatic Encephalopathy (Phase 3)
Hepatitis B, Chronic (Phase 2)
Hepatitis C (Phase 2/Phase 3)
Hepatitis C, Chronic (Phase 4)
HIV Infections (Phase 3)
Influenza, Human (Phase 3)
Intestinal Diseases (Phase 2/Phase 3)
Irritable Bowel Syndrome (Phase 4)
Kidney Diseases (Phase 1)
Kidney Failure, Chronic (Phase 1)
Liver Cirrhosis (Phase 2)
Liver Diseases (Phase 1)
Lung Diseases (Phase 3)
Malnutrition (Phase 2/Phase 3)
Neoplasms (Phase 2)
Non-alcoholic Fatty Liver Disease (Phase 2)
Periodontitis (Phase 2)
Peritonitis (Phase 3)
Pharmacokinetics (Phase 3)
Pneumonia (Phase 2)
Pneumonia, Viral (Phase 2)
Protozoan Infections (Phase 1/Phase 2)
Rhinovirus (Phase 3)
Rotavirus Infections (Phase 2/Phase 3)
SARS-CoV-2 (Phase 2/Phase 3)
Severe Acute Respiratory Syndrome (Phase 2)
Sexually Transmitted Diseases (Phase 2/Phase 3)
Tuberculosis (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue